Joshua Reed serves as Senior Vice President and Chief Financial Officer at Alkermes plc, a global biopharmaceutical company focused on developing innovative medicines for neurological and psychiatric disorders. Appointed to this role in March 2021, Reed brings over two decades of experience in finance leadership within the biotechnology and pharmaceutical sectors. Prior to joining Alkermes, he was Chief Financial Officer at bluebird bio, Inc., where he oversaw financial strategy during a period of rapid clinical advancement and capital raises exceeding $1 billion. His earlier career included key positions at Biogen, such as Vice President of Finance and Treasurer, where he managed global treasury operations, investor relations, and financial planning for a portfolio of blockbuster therapies. Throughout his tenure at Biogen from 2007 to 2019, Reed played a pivotal role in supporting the company's growth from a mid-sized biotech to a global leader, contributing to multiple successful product launches and mergers, including the $5.7 billion acquisition of Biogen Idec. His expertise in capital markets enabled efficient financing strategies that fueled R&D investments and sustained double-digit revenue growth. Reed holds a Bachelor of Science in Finance from Bentley University and an MBA from Babson College, and he is a Certified Public Accountant. At Alkermes, Reed leads the global finance organization, driving financial discipline amid complex product pipelines and strategic partnerships. Under his guidance, the company has optimized its cost structure, strengthened its balance sheet, and advanced key initiatives like the commercialization of Vivitrol and Aristada, while navigating regulatory and market challenges. His strategic vision has positioned Alkermes for long-term sustainability, earning recognition from investors for transparent reporting and prudent capital allocation.